Wells Fargo & Company Biomea Fusion, Inc. Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
A detailed history of Wells Fargo & Company transactions in Biomea Fusion, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 8,849 shares of BMEA stock, worth $92,737. This represents 0.0% of its overall portfolio holdings.
Number of Shares
8,849
Previous 5,974
48.13%
Holding current value
$92,737
Previous $89,000
56.18%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding BMEA
# of Institutions
119Shares Held
17.9MCall Options Held
978KPut Options Held
286K-
Cormorant Asset Management, LP Boston, MA3.57MShares$37.4 Million1.24% of portfolio
-
Black Rock Inc. New York, NY2.34MShares$24.6 Million0.0% of portfolio
-
Baker Bros. Advisors LP New York, NY2.11MShares$22.1 Million0.13% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.39MShares$14.6 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA1.1MShares$11.5 Million0.01% of portfolio
About Biomea Fusion, Inc.
- Ticker BMEA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,290,600
- Market Cap $307M
- Description
- Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in onc...